108 related articles for article (PubMed ID: 9619822)
1. HIV-1 in the female genital tract and the effect of antiretroviral therapy.
Cu Uvin S; Caliendo AM; Reinert SE; Mayer KH; Flanigan TP; Carpenter CC
AIDS; 1998 May; 12(7):826-7. PubMed ID: 9619822
[No Abstract] [Full Text] [Related]
2. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy.
Stellbrink HJ; Eggers C; van Lunzen J; Albrecht H; Greten H
AIDS; 1997 Nov; 11(13):1655-7. PubMed ID: 9365775
[No Abstract] [Full Text] [Related]
3. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
[No Abstract] [Full Text] [Related]
4. HAART reduces virus in women's genital tracts.
AIDS Alert; 1999 Mar; 14(3):30-1. PubMed ID: 11366213
[TBL] [Abstract][Full Text] [Related]
5. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
[TBL] [Abstract][Full Text] [Related]
6. Rebound of HIV-1 viral load after suppression to very low levels.
Staszewski S; Miller V; Sabin C; Berger A; Hill AM; Phillips AN
AIDS; 1998 Dec; 12(17):2360. PubMed ID: 9863886
[No Abstract] [Full Text] [Related]
7. Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Antinori A; Trotta MP; Lorenzini P; Torti C; Gianotti N; Maggiolo F; Ceccherini-Silberstein F; Nasto P; Castagna A; De Luca A; Mussini C; Andreoni M; Perno CF;
Antivir Ther; 2007; 12(8):1175-83. PubMed ID: 18240858
[TBL] [Abstract][Full Text] [Related]
8. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women.
Tuomala RE; O'Driscoll PT; Bremer JW; Jennings C; Xu C; Read JS; Matzen E; Landay A; Zorrilla C; Blattner W; Charurat M; Anderson DJ;
J Infect Dis; 2003 Feb; 187(3):375-84. PubMed ID: 12552421
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
10. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection.
Fialaire P; Payan C; Vitour D; Chennebault JM; Loison J; Pichard E; Lunel F
J Infect Dis; 1999 Aug; 180(2):574-5. PubMed ID: 10395889
[No Abstract] [Full Text] [Related]
11. Early increase in cell-associated HIV-1 DNA in patients on highly active antiretroviral therapy.
Galli M; Balotta C; Meroni L; Colombo MC; Papagno L; Bagnarelli P; Testa L; Varchetta S; Colombo L; Moroni M; d'Arminio Monforte A; Clerici M; Clementi M
AIDS; 1998 Dec; 12(18):2500-2. PubMed ID: 9875591
[No Abstract] [Full Text] [Related]
12. Vaccination and HIV-1 replication during highly active antiretroviral therapy.
Kroon FP; Beersma MF; Kroes AC; Groeneveld PH; van Dissel JT
AIDS; 1999 Jan; 13(1):135-6. PubMed ID: 10207556
[No Abstract] [Full Text] [Related]
13. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
14. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
15. Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.
Si-Mohamed A; Kazatchkine MD; Heard I; Goujon C; Prazuck T; Aymard G; Cessot G; Kuo YH; Bernard MC; Diquet B; Malkin JE; Gutmann L; Bélec L
J Infect Dis; 2000 Jul; 182(1):112-22. PubMed ID: 10882588
[TBL] [Abstract][Full Text] [Related]
16. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
Pulido F; Arribas JR; Delgado R; Cabrero E; González-García J; Pérez-Elias MJ; Arranz A; Portilla J; Pasquau J; Iribarren JA; Rubio R; Norton M;
AIDS; 2008 Jan; 22(2):F1-9. PubMed ID: 18097218
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological exposure and the development of drug resistance in HIV.
Hoetelmans R
Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
[No Abstract] [Full Text] [Related]
20. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy.
Medeiros RP; Munerato P; Diaz RS
J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
